These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38626241)

  • 41. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy.
    Veeraraghavan B; Bakthavatchalam YD; Sahni RD
    Infect Dis Ther; 2021 Mar; 10(1):15-25. PubMed ID: 33306184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Switching from CLSI to EUCAST XL susceptibility breakpoint: its implication in urinary tract infection in men.
    Aguirre-Quiñonero A; Lecaroz Agara MC; Canut Blasco A
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1813-1815. PubMed ID: 29936620
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.
    Bartsch SM; Huang SS; Wong KF; Slayton RB; McKinnell JA; Sahm DF; Kazmierczak K; Mueller LE; Jernigan JA; Lee BY
    J Clin Microbiol; 2016 Nov; 54(11):2757-2762. PubMed ID: 27582516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2015 Mar; 53(3):816-23. PubMed ID: 25540403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial susceptibility testing of Eggerthella lenta blood culture isolates at a university hospital in Belgium from 2004 to 2018.
    Declerck B; Van der Beken Y; De Geyter D; Piérard D; Wybo I
    Anaerobe; 2021 Jun; 69():102348. PubMed ID: 33596468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
    DeRyke CA; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli.
    María DA; María-Isabel M; María-Carmen C; Álvaro P; Jorge C; Luis MM; Francesc M; Jordi V; Adriana O; Jesús O; Rafael C
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):334-6. PubMed ID: 26830054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?
    Marchese A; Esposito S; Barbieri R; Bassetti M; Debbia E
    BMC Infect Dis; 2012 Aug; 12():181. PubMed ID: 22866984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Tunger A; Sancak B; Bıçakçıgil A; Altun B; Aktas Z; Kayacan C; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i88-i99. PubMed ID: 32337598
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microbiology of acute otitis media recently treated with aminopenicillins.
    Block SL; Hedrick JA; Tyler RD; Smith RA; Harrison CJ
    Pediatr Infect Dis J; 2001 Nov; 20(11):1017-21. PubMed ID: 11734704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes.
    Díez-Aguilar M; Morosini MI; López-Cerero L; Pascual Á; Calvo J; Martínez-Martínez L; Marco F; Vila J; Ortega A; Oteo J; Cantón R
    J Antimicrob Chemother; 2015 Aug; 70(8):2306-10. PubMed ID: 25900161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam.
    Van PH; Binh PT; Minh NH; Morrissey I; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i93-102. PubMed ID: 27048586
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Gupta A; Malik S; Kaminski M; Landman D; Quale JM
    Microb Drug Resist; 2022 Apr; 28(4):419-424. PubMed ID: 35451880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is chloramphenicol making a comeback?
    Nitzan O; Suponitzky U; Kennes Y; Chazan B; Raul R; Colodner R
    Isr Med Assoc J; 2010 Jun; 12(6):371-4. PubMed ID: 20928993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Breakpoint beware: reliance on historical breakpoints for Enterobacteriaceae leads to discrepancies in interpretation of susceptibility testing for carbapenems and cephalosporins and gaps in detection of carbapenem-resistant organisms.
    Yarbrough ML; Wallace MA; Potter RF; D'Souza AW; Dantas G; Burnham CD
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):187-195. PubMed ID: 31679102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.